Pharmacy Medical News about advanced-stage Hodgkins lymphoma;escalated-dose BEACOPP

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkins lymphoma: 10 years of follow-up of the GHAG HD9 study
Journal of Clinical Oncology, 08/31/09

Engert A et al. – The 10-y f/u of the HD9 trial demonstrates a stabilized significant improvement in long-term FFTF and OS for BEACOPP escalated in advanced stage HL, thus challenging ABVD as standard of care for this patient population.

Methods

1196 patients with advanced stage HL received 1 of 3 chemotherapy regimens: 8 cycles of COPP, alternating with ABVD 8 cycles of BEACOPP baseline; or 8 cycles of BEACOPP escalated

Results

Median f/u was 111 mos
at 10 y, freedom from treatment failure (FTFF) was 64%, 70%, and 82% with OS rates of 75%, 80%, and 86% COPP/ABVD, BEACOPP baseline, and BEACOPP escalated, respectively
BEACOPP escalated was significantly better than BEACOPP baseline in terms of FFTF and OS
The corresponding overall secondary malignancy rates were 5.7%, 6.6%, and 6.0%, respectively

<< Previous
A Clinician's Perspective on Rating the Strength of Evidence in a...

Next >>
Phase III randomized study of bendamustine compared with...

Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma
Leukemia and Lymphoma, 11/06/09 Relevance Score: 80%

Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes
Leukemia and Lymphoma, 11/04/09 Relevance Score: 80%

Hodgkin's lymphoma in remission after first-line therapy: Which patients need FDG-PET/CT for follow-up?
Annals of Oncology, 11/17/09 Relevance Score: 79%

Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09 Relevance Score: 70%

Sperm quality before treatment in patients with early stage Hodgkin lymphoma enrolled in EORTC-GELA Lymphoma Group trials
Haematologica, 10/27/09 Relevance Score: 69%